Third Opinion

Promising Clinical Trials For Hydrocephalus Without Surgery

Hydrocephalus is a serious brain condition that mostly affects babies under one year old (although it is not limited to infants). It can make them very sick. Doctors usually treat Hydrocephalus by putting a tube called a shunt in the baby's brain and tummy.

Alternatives to an invasive shunt treatment with surgery are becoming more popular in promising clinical research trials. This post analyzes current hydrocephalus clinical trials that may or may not use surgery as a form of treatment.

"Minimally Invasive" Surgery Hydrocephalus Clinical Trial

Third Opinion Trial Page Link

Name: US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Locations (All in U.S.): New York, Connecticut

Eligible Age: 65-85 years old

Trial Summary: The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction, and urinary incontinence.

Follow the link to view additional inclusion/exclusion criteria, and consult your doctor to determine whether this research opportunity may be a fit for you: https://www.thirdopinion.io/studies/NCT05232838

Hydrocephalus Data Collection Project

Third Opinion Trial Page Link

Name: HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)

Locations (All in U.S.): Alabama, California, Colorado, Maryland, Missouri, Ohio, Pennsylvania, Texas, Tennessee, Utah, Washington

Eligible Age: Not specified

Trial Summary (AI-Generated): A group called the Hydrocephalus Clinical Research Network, funded by donations and a grant from the National Institutes of Health, is doing research on pediatric hydrocephalus. They have different hospitals participating and a center to coordinate the data. They are collecting information about surgeries and treatments for hydrocephalus in kids to help doctors know what works best and make recommendations for patient care. They also hope to use the information to come up with new research ideas and see if there are any changes in how hydrocephalus affects kids over time. The project will continue for a long time and can help the network plan for the future and learn more about the children they are helping.

Hydrocephalus NIRS Monitoring In Premature Infants

Third Opinion Trial Page Link

Name: NIRS Monitoring In Premature Infants

Locations: Massachusetts (Boston)

Eligible Age: less than 40 weeks old

Trial Summary (AI-Generated): This study is looking at how a special technology can be used to measure blood flow and oxygen in the brains of newborn babies. The researchers are comparing babies with bleeding in their brains or swelling in their heads to healthy babies. They think that problems with how the brain uses energy might be a better way to tell how bad the bleeding or swelling is and how well treatment is working. The study has been approved by a hospital review board and is being done at different hospitals. Pei-Yi Lin is in charge of the study and is getting funding from the National Institute of Health.

Hydrocephalus Drug Trial Without Surgery

Third Opinion Trial Page Link

Name: Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Locations: Michigan (Ann Arbor)

Eligible Age: 18-80 years old

Trial Summary (AI-Generated): Aneurysmal subarachnoid hemorrhage (aSAH) is a serious condition where bleeding occurs in the brain, leading to a high chance of death or long-term problems. In the first two days after the bleeding starts, more than 30% of people with aSAH pass away. This happens because the brain is under a lot of pressure, swells up, and gets injured due to the release of iron. Iron also increases the chances of swelling, lack of blood flow, and water buildup in the brain. Deferoxamine mesylate (DFO), a type of medicine, can help by binding to the iron and stopping it from causing more damage. This study will look at how safe and helpful DFO is for treating aSAH. People who go to the hospital at the University of Michigan or Peking University Health Science Center and meet certain criteria can join the study. They will be randomly assigned to receive either a low or high dose of DFO or a fake treatment called a placebo. Doctors will collect information on the participants and follow up with them for up to six months after leaving the hospital.

Less Invasive Hydrocephalus Surgery Trial

Third Opinion Trial Page Link

Name: Pilot Study to Evaluate the CereVasc® eShunt® System in the Treatment of Communicating Hydrocephalus

Locations: New York, Connecticut

Eligible Age: 21+ years old

Trial Summary (AI-Generated): This study will look at a new way to treat hydrocephalus in grown-ups. The new method is called the eShunt® System. It uses a special device to put a permanent implant in the patient's brain in a less invasive way. This implant helps to remove extra fluid in the brain and move it into the veins.